doi:10.48130/vns-0026-0018

[1]

Wechalekar AD, Gillmore JD, Hawkins PN. 2016. Systemic amyloidosis. The Lancet 387:2641−2654

[2]

Ruiz-Medrano J, Puertas M, Almazán-Alonso E, Fernández-Jiménez M, Flores-Moreno I, et al. 2023. Ophthalmologic involvement in patients with hereditary transthyretin amyloidosis. Retina 43:49−56

doi: 10.1097/iae.0000000000003641

[3]

Gorevic PD, Rodrigues MM. 1994. Ocular amyloidosis. American Journal of Ophthalmology 117:529−532

doi: 10.1016/s0002-9394(14)70016-9

[4]

Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, et al. 2017. Ocular manifestations of familial transthyretin amyloidosis. American Journal of Ophthalmology 183:156−162

doi: 10.1016/j.ajo.2017.09.001

[5]

Buxbaum JN, Reixach N. 2009. Transthyretin: the servant of many masters. Cellular and Molecular Life Sciences 66:3095−3101

doi: 10.1007/s00018-009-0109-0

[6]

Dammacco R, Merlini G, Lisch W, Kivelä TT, Giancipoli E, et al. 2020. Amyloidosis and ocular involvement: an overview. Seminars in Ophthalmology 35:7−26

doi: 10.1080/08820538.2019.1687738

[7]

Minnella AM, Rissotto R, Antoniazzi E, Di Girolamo M, Luigetti M, et al. 2021. Ocular involvement in hereditary amyloidosis. Genes 12:955

doi: 10.3390/genes12070955

[8]

Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, et al. 2014. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Human Mutation 35:E2403−E2412

doi: 10.1002/humu.22619

[9]

Iakovleva I, Hall M, Oelker M, Sandblad L, Anan I, et al. 2021. Structural basis for transthyretin amyloid formation in vitreous body of the eye. Nature Communications 12:7141

doi: 10.1038/s41467-021-27481-4

[10]

Treviño-Herrera AB, Bustamante-Vargas AP, Lisker-Cervantes A, Ríos Y Valles Valles D, Villanueva-Mendoza C, et al. 2022. Vitreous involvement as initial presentation of hereditary transthyretin amyloidosis related to the rare TTR Ile107Met (p.Ile127Met) pathogenic variant. Ophthalmic Genetics 43:413−419

doi: 10.1080/13816810.2022.2025606

[11]

Du K, Li F, Wang H, Miao Y, Lv H, et al. 2021. Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study. Annals of Clinical and Translational Neurology 8:831−841

doi: 10.1002/acn3.51328

[12]

He X, Tian Z, Guan H, Zhang S. 2022. Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China. Orphanet Journal of Rare Diseases 17:337

doi: 10.1186/s13023-022-02481-9

[13]

Xu J, Shu N, Liu X, Gu P, Wang Y, et al. 2025. Long-term follow-up of retinal amyloid angiopathy in a large Chinese family with hereditary amyloid transthyretin. BMC Ophthalmology 25:251

doi: 10.1186/s12886-025-04059-y

[14]

Xu JN, Zhou Q, Yang ZL, Lin Y, Wang Y. 2013. Clinical characteristics and gene analysis of vitreous amyloidosis in a Chinese kindreds. Chinese Journal of Experimental Ophthalmology 31:471−475 (in Chinese)

doi: 10.3760/cma.j.issn.2095-0160.2013.05.013

[15]

Chen X, Xin C, Su G, Xie B, Li H, et al. 2025. Hereditary vitreoretinal amyloidosis with transthyretin Gly83Arg variant, a long-term study. Eye 39:345−353

doi: 10.1038/s41433-024-03445-y

[16]

Su G, Chen XW, Pan JL, Li H, Xie B, et al. 2023. Clinical features of retinal amyloid angiopathy with transthyretin Gly83Arg variant. International Journal of Ophthalmology 16:128−134

doi: 10.18240/ijo.2023.01.19

[17]

Xie B, Cai SJ, Jiang M, Li H, Su G. 2017. Familial vitreous amyloidosis resulting from transthyretin variant Gly83Arg. Acta Ophthalmologica 95:e520−e521

doi: 10.1111/aos.13425

[18]

Xiong Y, Qu G, Lu X, Chang X, Zhang M, et al. 2024. The Gly103Arg variant in hereditary transthyretin amyloidosis. Frontiers in Neurology 15:1471131

doi: 10.3389/fneur.2024.1471131

[19]

Feng YB, Shi YB, He YY, Ma ZY, Zhu YX, et al. 2023. Rare manifestation of familial vitreous amyloidosis caused by Gly103Arg transthyretin. International Journal of Ophthalmology 16:1093−1099

doi: 10.18240/ijo.2023.07.14

[20]

Shen J, Yu H, Lin J, Zhang L, Pan X, et al. 2022. Case Report: Hereditary transthyretin (ATTRv) amyloidosis: the p.G103R mutation of the transthyretin gene in a Han Chinese family is associated with vitreous hemorrhage. Frontiers in Genetics 13:972501

doi: 10.3389/fgene.2022.972501

[21]

Li Z, Du K, Chu X, Lv H, Zhang W, et al. 2022. TTR Gly83Arg mutation: beyond familial vitreous amyloidosis. Frontiers in Neurology 12:821003

doi: 10.3389/fneur.2021.821003

[22]

Yu Q, Huang X, Yang Z, Wang X. 2021. Clinical characteristics and genetic mutation analysis in a family with familial vitreous amyloidosis. Chinese Journal of Experimental Ophthalmology 39:719−723 (in Chinese)

doi: 10.3760/cma.j.cn115989-20190923-00412

[23]

Yin J, Xia X, Shi Y, Lu Y, Zhao C, et al. 2014. Chinese familial transthyretin amyloidosis with vitreous involvement is associated with the transthyretin mutation Gly83Arg: a case report and literature review. Amyloid 21:140−142

doi: 10.3109/13506129.2014.892871

[24]

Liu T, Zhang B, Jin X, Wang W, Lee J, et al. 2014. Ophthalmic manifestations in a Chinese family with familial amyloid polyneuropathy due to a TTR Gly83Arg mutation. Eye 28:26−33

doi: 10.1038/eye.2013.217

[25]

Zhang AM, Wang H, Sun P, Hu QX, He Y, et al. 2013. Mutation p. G83R in the transthyretin gene is associated with hereditary vitreous amyloidosis in Han Chinese families. Molecular Vision 19:1631−1638

[26]

Xie Y, Zhao Y, Zhou JJ, Wang X. 2012. Identification of a TTR gene mutation in a family with hereditary vitreous amyloidosis. Chinese Journal of Medical Genetics 29:13−15 (in Chinese)

doi: 10.3760/cma.j.issn.1003-9406.2012.01.004

[27]

Chen LY, Lu L, Li YH, Zhong H, Fang W, et al. 2011. Transthyretin Arg-83 mutation in vitreous amyloidosis. International Journal of Ophthalmology 4:329−331

doi: 10.3980/j.issn.2222-3959.2011.03.26

[28]

Chen L, Lü L, Zhang P, Li Y, Lin J. 2008. Transthyretin Arg-83 mutation in vitreous amyloidosis. Eye Science 24:65−67 (in Chinese)

doi: 10.3969/j.issn.1000-4432.2008.01.016

[29]

Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, et al. 2022. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid 29:213−219

doi: 10.1080/13506129.2022.2147636

[30]

Volpentesta E, Kharoubi M, Donadio C, Rebiai K, Fanen P, et al. 2024. Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy. ESC Heart Failure 11:3814−3832

doi: 10.1002/ehf2.14793

[31]

Ferguson JA, Sun X, Dyson HJ, Wright PE. 2021. Thermodynamic stability and aggregation kinetics of EF helix and EF loop variants of transthyretin. Biochemistry 60:756−764

doi: 10.1021/acs.biochem.1c00073

[32]

Aurora R, Srinivasan R, Rose GD. 1994. Rules for α-helix termination by glycine. Science 264:1126−1130

doi: 10.1126/science.8178170

[33]

Porcari A, Fontana M, Gillmore JD. 2023. Transthyretin cardiac amyloidosis. Cardiovascular Research 118:3517−3535

doi: 10.1093/cvr/cvac119

[34]

Dohrn MF, Medina J, Olaciregui Dague KR, Hund E. 2021. Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis. Neurological Research and Practice 3:57

doi: 10.1186/s42466-021-00155-8

[35]

Di Stefano V, Thomas E, Giustino V, Iacono S, Torrente A, et al. 2022. Motor conduction studies and handgrip in hereditary TTR amyloidosis: simple tools to evaluate the upper limbs. Frontiers in Neurology 13:835812

doi: 10.3389/fneur.2022.835812

[36]

Plante-Bordeneuve V. 2018. Transthyretin familial amyloid polyneuropathy: an update. Journal of Neurology 265:976−983

doi: 10.1007/s00415-017-8708-4

[37]

Kim D, Oh J, Min HK, Kim HR, Choi K. 2022. A pilot study of nailfold capillaroscopy in hereditary transthyretin amyloidosis. Scientific Reports 12:11715

doi: 10.1038/s41598-022-15779-2

[38]

Long D, Zeng J, Wu LQ, Tang LS, Wang HL, et al. 2012. Vitreous amyloidosis in two large mainland Chinese kindreds resulting from transthyretin variant Lys35Thr and Leu55Arg. Ophthalmic Genetics 33:28−33

doi: 10.3109/13816810.2011.599356

[39]

Carroll A, Dyck PJ, de Carvalho M, Kennerson M, Reilly MM, et al. 2022. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Journal of Neurology, Neurosurgery, and Psychiatry 93:668−678

doi: 10.1136/jnnp-2021-327909

[40]

Coelho T, Inês M, Conceição I, Soares M, de Carvalho M, et al. 2018. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 91:e1999−e2009

doi: 10.1212/wnl.0000000000006543

[41]

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, et al. 2018. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine 379:1007−1016

doi: 10.1056/NEJMoa1805689

[42]

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, et al. 2018. Inotersen treatment for patients with hereditary transthyretin amyloidosis. The New England Journal of Medicine 379:22−31

doi: 10.1056/NEJMoa1716793

[43]

Benson MD, Dasgupta NR, Rissing SM, Smith J, Feigenbaum H. 2017. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid 24:217−223

doi: 10.1080/13506129.2017.1374946

[44]

Coelho T, Adams D, Silva A, Lozeron P, Hawkins P, et al. 2013. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. New England Journal of Medicine 369:819−829

doi: 10.1056/NEJMoa1208760

[45]

Monteiro C, Martins da Silva A, Ferreira N, Mesgarzadeh J, Novais M, et al. 2018. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid 25:120−128

doi: 10.1080/13506129.2018.1479249

[46]

Kakihara S, Hirano T, Matsuda Y, Takano D, Imai A, et al. 2021. Deposits on retinal surface seen on OCT in ocular amyloidosis. Ophthalmology Retina 5:1005−1008

doi: 10.1016/j.oret.2020.12.028

[47]

Liu Z, Cui J, Lin Y. 2025. Curvilinear vitreous humor strands in hereditary transthyretin amyloidosis. Ophthalmology Retina 9:e75

doi: 10.1016/j.oret.2024.12.001

[48]

Kawaji T, Ando Y, Hara R, and Tanihara H. 2010. Novel therapy for transthyretin–related ocular amyloidosis: a pilot study of retinal laser photocoagulation. Ophthalmology 117:552−555

doi: 10.1016/j.ophtha.2009.07.042

[49]

Shao J, Xin Y, Li R, Fan Y. 2011. Vitreous and serum levels of transthyretin (TTR) in high myopia patients are correlated with ocular pathologies. Clinical Biochemistry 44:681−685

doi: 10.1016/j.clinbiochem.2011.03.032

[50]

Pepys MB. 2006. Amyloidosis. Annual Review of Medicine 57:223−241

doi: 10.1146/annurev.med.57.121304.131243

[51]

Miyata M, Sato T, Mizuguchi M, Nakamura T, Ikemizu S, et al. 2010. Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding. Biochemistry 49:114−23

doi: 10.1021/bi901677z

[52]

Hyung SJ, Deroo S, Robinson CV. 2010. Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chemical Biology 5:1137−1146

doi: 10.1021/cb100144v

[53]

Monaco HL, Rizzi M, Coda A. 1995. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268:1039−1041

doi: 10.1126/science.7754382